131 related articles for article (PubMed ID: 32162977)
21. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
[TBL] [Abstract][Full Text] [Related]
22. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
Igarashi T; Kobayashi Y; Ogura M; Kinoshita T; Ohtsu T; Sasaki Y; Morishima Y; Murate T; Kasai M; Uike N; Taniwaki M; Kano Y; Ohnishi K; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
Ann Oncol; 2002 Jun; 13(6):928-43. PubMed ID: 12123339
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
Monga N; Tam C; Garside J; Davids MS; Ward K; Quigley J; Parisi L; Tapprich C
Crit Rev Oncol Hematol; 2021 Feb; 158():103212. PubMed ID: 33383209
[TBL] [Abstract][Full Text] [Related]
24. Mantle cell lymphoma: state of the art.
Skarbnik AP; Goy AH
Clin Adv Hematol Oncol; 2015 Jan; 13(1):44-55. PubMed ID: 25679973
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
26. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
[TBL] [Abstract][Full Text] [Related]
27. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
28. Management of mantle cell lymphoma: key challenges and next steps.
Williams ME; Dreyling M; Winter J; Muneer S; Leonard JP
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):336-46. PubMed ID: 21030346
[TBL] [Abstract][Full Text] [Related]
29. CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients.
Miao Y; Lin P; Saksena A; Xu J; Wang M; Romaguera J; Yin CC; Medeiros LJ; Li S
Am J Surg Pathol; 2019 Aug; 43(8):1052-1060. PubMed ID: 31045891
[TBL] [Abstract][Full Text] [Related]
30. Current trials for frontline therapy of mantle cell lymphoma.
Steiner RE; Romaguera J; Wang M
J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
[TBL] [Abstract][Full Text] [Related]
31. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
32. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological Features of Ocular Adnexal Mantle-Cell Lymphoma in an International Multicenter Cohort.
Knudsen MKH; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Khong JJ; McKelvie PA; Mulay K; Ralfkiaer E; Sjö LD; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
JAMA Ophthalmol; 2017 Dec; 135(12):1367-1374. PubMed ID: 29121219
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
35. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome.
Cogliatti SB; Bertoni F; Zimmermann DR; Henz S; Diss TC; Ghielmini M; Schmid U
J Pathol; 2005 Jul; 206(3):320-7. PubMed ID: 15887292
[TBL] [Abstract][Full Text] [Related]
36. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
38. Burden of illness of follicular lymphoma and marginal zone lymphoma.
Monga N; Nastoupil L; Garside J; Quigley J; Hudson M; O'Donovan P; Parisi L; Tapprich C; Thieblemont C
Ann Hematol; 2019 Jan; 98(1):175-183. PubMed ID: 30315345
[TBL] [Abstract][Full Text] [Related]
39. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
40. Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the Surveillance, Epidemiology and End Results database.
Guru Murthy GS; Venkitachalam R; Mehta P
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S90-5. PubMed ID: 25486963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
